Ilana Kattan is a counsel in the Antitrust practice at Hogan Lovells and is based in the firm’s Washington, D.C. office. She represents companies before the antitrust enforcement agencies in connection with M&A, joint ventures, and conduct investigations. she also advises companies on a range of antitrust issues, including licensing agreements, joint ventures and other collaborations, and behavioral issues. Ilana works with companies across a wide range of industries, such as publishing, chemicals, industrials, healthcare, and technology. she has particular experience representing companies in the Life Sciences sector, where she regularly advises pharmaceutical and medical device companies on the antitrust risks of their M&A and licensing and collaboration agreements and help shepherd them through complex merger control processes in the United States and abroad.
140
On July 19, 2023 the Federal Trade Commission (FTC) and Department of Justice (DOJ) (“the agencies”) released their 2023 Draft Merger Guidelines (the “2023 draft guidelines” or the “revised guidelines”). The publication of the revised guidelines—currently available for public comment until (...)
46
On July 19, 2023 the Federal Trade Commission (FTC) and Department of Justice (DOJ) (“the agencies”) released their 2023 Draft Merger Guidelines (the “2023 draft guidelines” or the “revised guidelines”). The publication of the revised guidelines—currently available for public comment until (...)
159
On July 14, 2023 the Federal Trade Commission (FTC) announced that it is withdrawing two antitrust policy statements related to antitrust enforcement in health care markets (the policy statements). Specifically, the FTC is withdrawing “safe harbors” for healthcare provider mergers, joint (...)
186
On June 15, 2023 the US Federal Trade Commission’s (FTC) Bureau of Competition (the Bureau) issued a statement outlining its view that the enforcement of certain contract terms “can impede the Bureau’s law enforcement investigations of potentially harmful mergers and conduct” and are therefore (...)
644
On 19 October 2022, the Antitrust Division of the US Department of Justice (the Division) announced that seven directors have agreed to resign from the boards of directors of five companies in response to the Division’s “competition concerns” related to the Clayton Act’s prohibition on (...)
1000
On the heels of two successful hospital merger challenges in the last year, the FTC announced on Thursday that it is bringing two new cases seeking to block proposed hospital transactions: RWJBarnabas Health’s (RWJ’s) acquisition of Saint Peter’s Healthcare System (Saint Peter’s) in New Jersey (...)
